Showing 38,941 - 38,960 results of 42,065 for search '"China"', query time: 0.19s Refine Results
  1. 38941
  2. 38942
  3. 38943
  4. 38944
  5. 38945
  6. 38946
  7. 38947
  8. 38948

    Behaviors and influencing factors of Chinese oncology nurses towards frailty care: A cross-sectional study based on knowledge-attitude-practice theory in 2024. by Xiaoxue Chen, Fang Xiao, Yuhua Miao, Huiying Qin, Lirong Yang, Fang Shen, Xiuhong Yuan

    Published 2025-01-01
    “…In China, a "Secondary A hospital is a mid-tier hospital that provides comprehensive medical care and handles more complex cases than primary hospitals but is smaller and less specialized than tertiary hospitals. …”
    Get full text
    Article
  9. 38949

    Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus by Li X, Cao K, Fu Z, Chen X, Zhong J, Liu L, Ding N, Zhang X, Qu Z, Zhu L, Zhai J

    Published 2025-01-01
    “…Xiaowei Li,* Kunkun Cao,* Zhigang Fu,* Xiaoxia Chen, Jiaming Zhong, Li Liu, Ning Ding, Xiaoli Zhang, Zengqiang Qu, Lijun Zhu, Jian Zhai Department II of Interventional Radiology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jian Zhai; Lijun Zhu, Department II of Interventional Radiology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People’s Republic of China, Email jianzhai1979@126.com; lijun_zhush@163.comPurpose: To assess the activity and toxicity of hepatic arterial infusion chemotherapy (HAIC)+tislelizumab+lenvatinib (HAIC+tisle+len) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) type IV (Vp4 hCC) in a real-world context.Methods: Fifty-five patients, with Vp4 hCC receiving HAIC+tisle+len therapy from April 2021 to December 2022, were analyzed retrospectively. …”
    Get full text
    Article
  10. 38950
  11. 38951

    Rapid Verbal Persuasion to increase influenza vaccine uptake: protocol for a randomized hybrid type 2 effectiveness -implementation trial by Siyuan Liu, Lan Gao, Yingying Jin, Jiangyun Chen, Dadong Wu, Yiyuan Cai, Tao Wang, Sanhao Huang, Ciling Yan, Run Wang, Dong Roman Xu

    Published 2025-02-01
    “…Abstract Background While influenza vaccines are the most effective measure for preventing influenza, uptake rates in China remain relatively low. Rapid Verbal Persuasion (RVP), with highly rapid fashion, has a strong evidence base in promoting behavior change. …”
    Get full text
    Article
  12. 38952
  13. 38953
  14. 38954
  15. 38955
  16. 38956
  17. 38957
  18. 38958

    Identification of EGR1 as a Key Diagnostic Biomarker in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Through Machine Learning and Immune Analysis by Wu X, Pan T, Fang Z, Hui T, Yu X, Liu C, Guo Z, Liu C

    Published 2025-02-01
    “…Xuanlin Wu, Tao Pan, Zhihao Fang, Titi Hui, Xiaoxiao Yu, Changxu Liu, Zihao Guo, Chang Liu Department of General Surgery, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, People’s Republic of ChinaCorrespondence: Chang Liu, Department of General Surgery, Fourth Affiliated Hospital of Harbin Medical University, 37 Yiyuan Street, Nangang District, Harbin, Heilongjiang, 150001, People’s Republic of China, Tel +86-13313699697, Email lc19726666@163.comBackground: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), as a common chronic liver condition globally, is experiencing an increasing incidence rate which poses significant health risks. …”
    Get full text
    Article
  19. 38959
  20. 38960